Equities

Faron Pharmaceuticals Oy

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Faron Pharmaceuticals Oy

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)207.50
  • Today's Change-7.50 / -3.49%
  • Shares traded5.85k
  • 1 Year change+64.03%
  • Beta1.6915
Data delayed at least 20 minutes, as of Jul 11 2025 16:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-22.44m
  • Incorporated2006
  • Employees25.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151
  • Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
hVIVO PLC62.73m10.65m68.70m301.006.461.524.831.100.01550.01550.09110.06570.7289--4.20208,388.7012.385.5120.2810.35----16.986.731.86--0.224167.0911.9279.44-33.90--154.59--
Scancell Holdings Plc0.00-15.81m106.27m61.00---------0.0171-0.01710.00-0.0150.00----0.00-81.40-31.66-625.06-37.66-------822.37---42.23251.00---100.00--50.91--131.54--
Avacta Group Plc11.26m-29.43m123.80m151.00--12.74--10.99-0.085-0.14960.03270.02510.18540.002.6474,576.16-48.46-43.48-172.33-78.2744.5963.54-261.32-781.441.08-0.57120.7229---96.04---0.9503------
Bioventix PLC13.66m7.85m144.99m17.0018.7412.8418.2310.611.481.482.582.161.042.172.21803,738.3059.9858.3369.0663.6290.9593.0957.4264.126.69--0.0090.926.177.93-3.296.67-28.4016.25
4Basebio PLC933.00k-12.33m155.09m----5.87--166.23-0.9391-0.93910.07111.700.03290.85844.78---43.54-36.81-48.26-40.9867.5269.88-1,321.87-1,160.8311.18-19.680.3658--84.3935.80-60.90--50.57--
Faron Pharmaceuticals Oy0.00-22.44m233.36m25.00---------0.2682-0.26820.00-0.08080.00----0.00-227.96-227.46---1,738.54-----------2.585.15------16.24--17.71--
Puretech Health PLC3.58m39.64m315.10m56.007.421.0213.5788.100.17640.17640.0141.280.0075--2.4863,867.544.29-3.274.57-3.83----575.43-253.25----0.052--44.98-13.21181.45-33.81-75.53--
Oxford BioMedica plc128.80m-43.19m373.60m861.00--6.54--2.90-0.414-0.4141.240.53840.53225.734.71149,590.00-20.09-20.23-25.99-25.4841.1749.36-37.74-45.032.05-5.420.6426--43.8414.9972.58---21.89--
Allergy Therapeutics plc55.66m-35.65m393.23m602.00------7.07-0.0075-0.00750.0117-0.00150.78362.156.0092,453.49-50.19-22.88-78.92-30.1554.0466.47-64.05-24.881.15-4.071.19---7.36-5.626.63--1.88--
Data as of Jul 11 2025. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX

Institutional shareholders

11.82%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 24 Jun 20244.60m4.11%
Fj�rde AP-fondenas of 06 Feb 20253.15m2.81%
OP Asset Management Ltd.as of 30 Jun 20242.68m2.39%
Sp-Fund Management Co. Ltd.as of 30 Jun 20251.58m1.41%
Danske Bank A/S (Investment Management Finland)as of 31 May 2024431.72k0.39%
Fondita Fund Management Co. Ltd.as of 31 May 2024330.49k0.30%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2024162.28k0.15%
Veikko Laine Oyas of 31 May 2024148.00k0.13%
Janus Henderson Investors UK Ltd.as of 31 May 2025100.00k0.09%
Alphajet Fair Investors SASas of 02 Jul 202550.00k0.05%
More ▼
Data from 31 Jul 2024 - 02 Jul 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.